Mobilion secures $60M for biologic therapeutic characterization

By The Science Advisory Board staff writers

July 13, 2021 -- Mobilion Systems has netted $60 million in a series C financing round.

The round was led by D1 Capital Partners, with additional participation from existing investors aMoon, Agilent Technologies, IP Group, Hostplus, and Cultivation Capital, according to Mobilion.

The company said that the proceeds will be used to expand commercial activities for its recently launched Mobie high-resolution ion mobility (HRIM) mass spectrometry instrument, which is designed to improve characterization during biopharmaceutical drug development and quality monitoring.

In addition, Mobilion plans to use some of the funds to accelerate product development for expansion into the bioprocessing and multiomic biomarker discovery markets.

Mobilion launches Mobie mass spectrometer
Mobilion Systems has launched a high-resolution ion mobility mass spectrometry instrument called Mobie for biopharmaceutical drug development and workflows...

Copyright © 2021

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter